SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets. The ferret model is widely considered to be the most representative of human influenza; achieving in ferrets a level of antibody titers commonly associated with protection in humans is a critical milestone in influenza vaccine development. Dr. Niranjan Y. Sardesai, Inovio’s Sr. VP, Research and Development, presented this data at the Vaccine 3rd Global Congress in Singapore in a presentation entitled, “Development of Universal SynCon™ DNA Vaccines for Pandemic and Seasonal Flu.”
